5002-47-1

Basic information

• Product Name: Fluphenazine decanoate
• Synonyms: 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyld;dapotumd;decanoicacid,2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-pipera;ecanoate;flufenazinedecanoate;fluorophenazinedecanoate;fluphenazinedepot;lyogen
• CAS NO: 5002-47-1
• Molecular Formula: C₃₂H₄₄F₃N₃O₂S
• Molecular Weight: 591.77
• EINECS: 225-672-4
• Product Categories: Organics;API
• Mol File: 5002-47-1.mol
• Article Data: 0

Chemical Properties

• Melting Point: 30-32°
• Boiling Point: 658.1 °C at 760 mmHg
• Flash Point: 351.8 °C
• Appearance: /
• Density: 1.149 g/cm³
• Vapor Pressure: 3.4E-17mmHg at 25°C
• Refractive Index: 1.537
• Solubility: Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol.
• PKA: 7.32±0.10(Predicted)
• CAS DataBase Reference: Fluphenazine decanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Fluphenazine decanoate(5002-47-1)
• EPA Substance Registry System: Fluphenazine decanoate(5002-47-1)

Safety Data

• RIDADR: 3249
• RTECS: HE0525000
• HazardClass: 6.1(a)
• PackingGroup: II
• Hazardous Substances Data: 5002-47-1(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Oil

Uses

Fluphenazine Decanoate is used in psychotropic drug treatments like those relating to schizophrenia. Antipsychotic.

Clinical Use

AntipsychoticSchizophrenia and other psychoses

Drug interactions

Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids. Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; increased risk of ventricular arrhythmias with amiodarone and dronedarone - avoid; increased risk of ventricular arrhythmias with disopyramide.Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin - avoid Antidepressants: increased risk of ventricular arrhythmias with tricyclics, citalopram, escitalopram; possible increased risk of convulsions with vortioxetineAntiepileptics: antagonises anticonvulsant effect.Antimalarials: increased risk of ventricular arrhythmias with artenimol with piperaquine and artemether/lumefantrine - avoid.Antipsychotics: increased risk of ventricular arrhythmias with droperidol, pimozide and risperidone - avoid; avoid use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs).Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir.Anxiolytics and hypnotics: increased sedative effectsAtomoxetine: increased risk of ventricular arrhythmias.Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalolCytotoxics: increased risk of ventricular arrhythmias with arsenic trioxideDiuretics: enhanced hypotensive effect.Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.Pentamidine: increased risk of ventricular arrhythmias - avoid.Avoid with drugs that prolong the QT interval.

Metabolism

The cytochrome P450 isoenzyme CYP2D6 is involved in fluphenazine metabolism.

InChI:InChI=1/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3